

Superiority of Bone Marrow derived-Osteoblastic Cells (ALLOB[®]) over Bone Marrow derived-Mesenchymal Stromal Cells

Sandra Pietri, PhD, H el ene Dubout, MSc, Sabrina Ena, PhD, and Enrico Bastianelli, MD, MBA.
Bone Therapeutics S.A., 37 rue Auguste Piccard, 6041 Gosselies, Belgium


SUMMARY

Bone Therapeutics is a bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair, more specifically in non-union and delayed-union fractures – and spinal fusion - where the bone repair process is impaired. The company has developed a unique allogeneic osteoblastic cell product (ALLOB[®]) derived from bone marrow which is currently tested in three Phase I/IIa proof of concept clinical trials. The purpose of the study was to directly compare ALLOB[®] vs. non-differentiated mesenchymal stromal cells (MSC) for their *in vitro* osteogenic characteristics and their *in vivo* osteogenic potential in order to determine which cellular type would be the most adapted for bone repair.

Declaration of Conflict of Interest: All authors have no potential conflict of interest to declare

METHODS

1. Culture and expansion of MSC and ALLOB[®] cells (n=7 Bone Marrow)




2. *In vitro* characterization (n=7)

Cells were characterized *in vitro* by morphology, immunophenotype (FACS), gene expression (qRT-PCR) and differentiation potential.

3. *In vivo* assessment of efficacy (n=6)

Subcutaneous injection over the calvaria of nude mice of

- MSC cells
- ALLOB[®] cells
- excipient (control -)




Bone formation evaluated by

- Radiology (Faxitron[®])
- Histomorphometry


RESULTS

1. Cells immunophenotype, ALP activity and morphology (n=7)

Cell population	Mesenchymal markers	Hematopoietic markers		Osteoblastic markers	
	FACS analysis				
	CD73/CD90/CD105	CD3	CD45	ALP	Enz. act. analysis ALP enz. (mU/mg tot. prot.)
MSC	99 ± 1 (n=7)	3 ± 1 (n=7)	2 ± 0 (n=7)	15 ± 7 (n=7)	108 ± 86 (n=7)
ALLOB [®]	100 ± 0 (n=7)	7 ± 0 (n=7)	1 ± 1 (n=7)	75 ± 7 (n=7)	495 ± 266 (n=7)




2. Analysis of chondro- and osteoblastic markers gene expression (n=7)




ALLOB[®] also expressed significantly higher levels of *Sox9* (fold change (FC) >5), *Ctsk* (FC > 200), *Bglap* (FC > 16), *Bmp2* (FC > 120) compared to MSC.

3. Bone Formation in NMRI-Nude mice

Histomorphometrical evaluation of the bone formation



Radiological evaluation of the bone formation



CONCLUSIONS

ALLOB[®] displays superior osteogenic capacity over BM-MSCs *in vitro* and *in vivo*, and is therefore a good clinical candidate.